期刊
JOURNAL OF NANOBIOTECHNOLOGY
卷 19, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12951-021-01085-y
关键词
Biomimetic nanoparticles; Hybrid nanovesicle; Tumor microenvironment activated; Glycolysis; Chemotherapy; Non-small cell lung cancer
资金
- Shanghai Rising Stars of Medical Talent Youth Development Program-Youth Medical Talents-Clinical Pharmacist Program
- Subject Construction Project of Shanghai Pulmonary Hospital
- National Natural Science Foundation of China [NSFC 81903141]
The research integrates cancer cell membranes with switchable peptide-based charge-reversal liposome membranes to create a hybrid nanoplatform for smart drug delivery. This platform demonstrates excellent drug release and targeted therapy effects triggered by pH and redox, with potential therapeutic applications for non-small cell lung cancer.
Background: Biomimetic nanotechnology-based RNA interference (RNAi) has been successful in improving theranostic efficacy in malignant tumors. Its integration with hybrid biomimetic membranes made of natural cell membranes fused with liposomal membranes is mutually beneficial and extends their biofunctions. However, limited research has focused on engineering such biomimetics to endow them with unique properties and functions, in particular, those essential for a smart drug delivery system, such as a tumor microenvironment (TME)-activated multifunctional biomimetic nanoplatform. Results: Herein, we utilized an integrated hybrid nanovesicle composed of cancer cell membranes (Cm) and matrix metallopeptidase 9 (MMP-9)-switchable peptide-based charge-reversal liposome membranes (Lipm) to coat lipoic acid-modified polypeptides (LC) co-loaded with phosphoglycerate mutase 1 (PGAM1) siRNA (siPGAM1) and DTX. The nanovesicle presented a negatively charged coating (citraconic anhydride-grafted poly-l-lysine, PC) in the middle layer for pH-triggered charge conversion functionalization. The established chemotherapeutic drug (DTX) co-delivery system CLip-PC@CO-LC nanoparticles (NPs) have a particle size of similar to 193 nm and present the same surface proteins as the Cm. Confocal microscopy and flow cytometry results indicated a greater uptake of MMP-9-treated CLip-PC@CO-LC NPs compared with that of the CLip-PC@CO-LC NPs without MMP-9 pretreatment. The exposure to MMP-9 activated positively charged cell-penetrating peptides on the surface of the hybrid nanovesicles. Moreover, pH triggered membrane disruption, and redox triggered DTX and siRNA release, leading to highly potent target-gene silencing in glycolysis and chemotherapy with enhanced antiproliferation ability. The biodistribution results demonstrated that the CLip-PC@LC-DiR NPs accumulated in the tumor owing to a combination of long blood retention time, homologous targeting ability, and TME-activated characteristics. The CLip-PC@CO-LC NPs led to more effective tumor growth inhibition than the DTX and free siPGAM1 formulations. Conclusions: TME-activated cancer cell membrane-liposome integrated hybrid NPs provide an encouraging nanoplatform that combines RNAi with chemotherapy for precise treatment of non-small cell lung cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据